Annovis Bio (NYSE:ANVS – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08, Zacks reports.
Annovis Bio Stock Performance
NYSE ANVS traded up $0.08 during trading hours on Friday, hitting $0.93. The company had a trading volume of 2,162,279 shares, compared to its average volume of 3,303,590. Annovis Bio has a 1-year low of $0.62 and a 1-year high of $5.50. The company has a market cap of $39.79 million, a PE ratio of -0.52 and a beta of 1.36. The business has a 50 day moving average of $1.10 and a 200-day moving average of $1.82.
Insider Activity
In other news, Director Michael Hoffman acquired 5,000,000 shares of the company’s stock in a transaction on Friday, November 6th. The shares were bought at an average price of $1.00 per share, with a total value of $5,000,000.00. Following the completion of the acquisition, the director owned 8,364,883 shares in the company, valued at $8,364,883. This trade represents a 148.59% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 15.92% of the company’s stock.
Wall Street Analysts Forecast Growth
ANVS has been the subject of a number of research analyst reports. Wall Street Zen raised Annovis Bio from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings lowered shares of Annovis Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Canaccord Genuity Group reissued a “buy” rating on shares of Annovis Bio in a report on Tuesday, August 18th. Finally, Roth Capital reduced their price objective on shares of Annovis Bio from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, August 27th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Annovis Bio currently has a consensus rating of “Hold” and a consensus price target of $12.00.
View Our Latest Report on Annovis Bio
About Annovis Bio
Annovis Bio is a clinical-stage biotechnology company based in Malvern, Pennsylvania. Founded in 2008, the company researches and develops treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.
Read More
- Five stocks we like better than Annovis Bio
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.
